Guided Cancer Therapeutics
Navigated Delivery™ technology for safer and more effective cancer drugs
Publication
Phase 1 | Solid Tumors
GDT-001 (IL12-FHAB)
A IL-12 immunotherapy candidate designed to be best-in-class for turning 'cold' tumors 'hot’ while avoiding systemic immune-activation toxic effects. Currently in Phase 1 for advanced solid tumors and in combination with trabectedin (Yondelis®) for Soft-Tissue Sarcomas. Currently seeking partnership to move this forward into Phase 1B/IIA.
Proprietary & validated delivery Platform
FHAB is a fully human, modular Navigated Delivery™ platform with clinical validation of proof of concept. It enables up to a 10-fold extension in serum half-life, enhanced accumulation and retention in tumor, and improved therapeutic activity. The FHAB platform enables delivery of a broad range of biologic payloads, including immune-modulating cytokines.
Active Clinical Pipeline
Therapeutic candidates across immuno-oncology and precision oncology mechanisms of action shows the versatility of the platform, with ongoing Phase 1 studies.
Built for Partnership
Our plug-and-play modular platform is compatible with many biologic drug classes, including interleukins, growth factors, cytokines, peptides, antibodies and vaccines, enabling rapid adaptation across modalities for co-development and licensing partnerships.
Guided by Expertise.
Driven by Purpose.
The Guidant BioTherapeutics team combines deep technical expertise in cytokine biology with extensive experience in drug discovery and development.
